Ikena Oncology, Inmagene Biopharmaceuticals appoint Kristin Yarema, as CEO

7 hours ago 1

Ikena Oncology (NASDAQ:IKNA) and Inmagene Biopharmaceuticals on Wednesday announced the appointment of Kristin Yarema, Ph.D. as chief executive officer of ImageneBio, of the combined company after the anticipated closing.
Kristin Yarema brings over two decades of leadership experience in human therapeutics to Imagene, the company said. Yarema joins the team after most recently serving as President and CEO and as a member of the Board of Directors of Poseida Therapeutics.
IKNA is +5.65% to $1.31.
Source: Press Release

Recommended For You